文献速递其他结缔组织病血管炎

血浆血管生物标志物在系统性硬化症中的应用:一项前瞻性纵向分析

The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis.
PubMed 文献 · Arthritis Rheumatol · 2020-07-20

该前瞻性队列纳入300例基线无肺动脉高压(PH)和/或活动性缺血性指端病变的系统性硬化症(SSc)患者,随访至少5年,评估血管生成相关生物标志物预测PH/缺血性指端病变的能力。基线HGF、sFlt-1和PLGF与PH发生显著相关,且基线升高的生物标志物数量与PH风险呈剂量反应关系。

要点

  • 基线HGF、sFlt-1和PLGF升高与SSc患者PH发生风险显著相关。
  • 基线每多一项升高的血管生物标志物,PH风险增加78%。
  • 未观察到临近PH诊断时生物标志物水平相应升高。

核心结论

  • 参与血管生成的分子反映血管扰动,初次评估时这些生物标志物升高可提示SSc患者存在PH发生风险。

研究设计与样本

  • 前瞻性队列研究纳入300例基线无PH和/或活动性缺血性指端病变的SSc患者,随访至少5年。
  • 在多个时间点检测HGF、sFlt-1、可溶性内皮糖蛋白、内皮抑素和PLGF水平,评估其预测PH/缺血性指端病变的能力。

主要发现

  • 基线HGF与PH发生相关:HR 1.99(95%CI 1.24-3.17),P=0.004。
  • 基线sFlt-1与PH发生相关:HR 3.04(95%CI 1.29-7.14),P=0.011。
  • 基线PLGF与PH发生相关:HR 2.74(95%CI 1.32-5.69),P=0.007。
  • 基线每增加一项升高的生物标志物,PH风险增加78%:HR 1.78(95%CI 1.2-2.6),P=0.004。

关键数值与推荐

  • 将每个连续血管生物标志物转换为二分类变量后,基线升高的生物标志物数量与PH发生风险呈剂量反应关系。

临床怎么用

  • 对基线无PH和活动性缺血性指端病变的SSc患者,可检测HGF、sFlt-1和PLGF以辅助识别PH高风险者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In cross-sectional studies, pulmonary hypertension (PH) and ischemic digital lesions are 2 scleroderma vascular outcomes associated with abnormalities in biomarkers of angiogenesis. The clinical usefulness of these biomarkers is unknown, in part due to lack of data on longitudinal measurement. This prospective longitudinal study was undertaken to evaluate vascular biomarker measurements in patients with systemic sclerosis (SSc) over time. METHODS: We conducted a prospective cohort study of 300 patients with SSc who were followed up for at least a 5-year period and lacked evidence of PH and/or active ischemic digital lesions at enrollment. Levels of hepatocyte growth factor (HGF), soluble Flt-1 (sFlt-1), soluble endoglin, endostatin, and placental growth factor (PLGF) were obtained at multiple time points and assessed for their ability to predict the development of PH/ischemic digital lesions. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated. RESULTS: Forty-six patients (15%) developed PH and 69 patients (23%) developed an ischemic digital lesion. In time-to-event analyses, the following 3 biomarkers measured at cohort entry were found to be significantly associated with the development of PH: HGF (HR 1.99 [95% CI 1.24-3.17], P = 0.004), sFlt-1 (HR 3.04 [95% CI 1.29-7.14], P = 0.011), and PLGF (HR 2.74 [95% CI 1.32-5.69], P = 0.007). As time approaching PH diagnosis decreased, there was no corresponding increase in any biomarker level. Upon converting each continuous vascular biomarker into a binary variable, a dose-response relationship was observed for the number of elevated biomarkers at cohort entry and the risk of developing PH. With each additional elevated biomarker at cohort entry, there was a 78% increase in the risk of developing PH (HR 1.78 [95% CI 1.2-2.6], P = 0.004). CONCLUSION: These data suggest that molecules involved in angiogenesis reflect vascular perturbation, and that elevations in these biomarkers at first encounter can indicate patients who are at risk of PH development.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Mecoli CA, Shah AA, Boin F, et al. The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis. Arthritis Rheumatol. 2020. PMID: 32200572. doi:10.1002/art.41265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。